Jamjoom Pharmaceuticals Factory Company SJSC (4015) fair value: what the stock is really worth
We calculate from audited financials what Jamjoom Pharmaceuticals Factory Company SJSC is really worth. The fair value tells you whether the price is too high or too low, the quality score (0 to 100) how solid the business behind it is. 26 models, 37 quality factors, updated daily.
Watch Jamjoom Pharmaceuticals Factory Company SJSC for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for free
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 13, 2026.
How to read this chart
39‑month range 71.88 SAR – 191.96 SAR · fair‑value band 81.63 SAR – 267.56 SAR · the 136.10 SAR price screens below the 150.92 SAR fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 13, 2026.
Jamjoom Pharmaceuticals Factory Company, together with its subsidiaries, engages in the manufacture and distribution of pharmaceutical and consumer products in the Kingdom of Saudi Arabia, Gulf, Iraq, Egypt, North Africa, and internationally.
Show more
Jamjoom Pharmaceuticals Factory Company, together with its subsidiaries, engages in the manufacture and distribution of pharmaceutical and consumer products in the Kingdom of Saudi Arabia, Gulf, Iraq, Egypt, North Africa, and internationally. It provides human medicines; nutraceuticals; antibiotics; general analgesics; medicines for treatment of cough, allergy, asthma, heart diseases, blood pressure, diarrhea, vomiting, and ulcer and acidity; treatment of various skin infections and cancer diseases; and eye drops, and ointments and cosmeceuticals. The company also offers ophthalmic solutions, dermatology products, cardiovascular health, consumer health, respiratory health, gastrointestinal health, endocrinology and diabetes care, central nervous system, and pain and inflammation pharmaceutical products. Jamjoom Pharmaceuticals Factory Company was founded in 1994 and is based in Jeddah, the Kingdom of Saudi Arabia.
Stock analysis
Jamjoom Pharmaceuticals Factory Company SJSC (4015) currently trades at 136.10 SAR, while our model-based Fair Value estimate is 150.92 SAR, implying the stock looks roughly 9.8% undervalued today.
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of 161.43 SAR per share, and 7 of the 24 models we run sit above the 136.10 SAR price.
Bear case: the Asset-Based group reads lowest at 16.43 SAR, and 17 of the 24 models stay below the price. Evidence for this calculation is high.
Scenario range: 81.63 SAR (bear) to 267.56 SAR (bull), the price of 136.10 SAR sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 77/100 (high quality), in the Healthcare sector.
Healthy Growth: Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Jamjoom Pharmaceuticals Factory Company SJSC reported revenue of 1.5B SAR in FY2025 versus 736M SAR in FY2021, a compound +19.5%/yr. Reported net income was 464M SAR in FY2025, compounding +28.4%/yr from FY2021.
Key figures
Market cap 9.6B SAR (≈ $2.5B) · P/E ratio 20.0 · P/S ratio 6.20 · EPS (TTM) 6.79 SAR · Dividend yield 3.1% · Net margin 30.9% · Return on equity 27.0% · Return on assets (EBIT) 18.7%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 52 out of 100 (medium confidence).
What moves the price
The share trades about 17% below its 52-week high and 11% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −17% fair-value upside, at 11%, 4015 screens cheaper than that median.
Fair Value models
Bear 81.63 SARFair Value 150.92 SARBull 267.56 SAR
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2025 figures (about 8 months old). Earnings retained since then (1.82 SAR per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.99/100
Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Revenue growth 1 year
+13.8%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+17.9%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+13.3%
Revenue growth 7 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+11.5%
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years) (mathematically smoothed) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Smoothed = median of all growth paths between the years of the window (trend line on the logarithm of earnings per share): a single extreme year cannot distort the rate. The reported figure stays in the tooltip.
+28.8%
Earnings growth per share plus dividend.
Earnings per share, growth per year+25.7%
Dividend (yield on the price)3.1%
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.31% → 32%
2025 sits 58% above its own trend. The rate follows the median trend of the last 5 years, not that single year.
Growth Forecast
Price in line with expectations
The price assumes about as much growth as the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+13.8%
Yearly growth needed for the next five years to justify today's price.
Compare Jamjoom Pharmaceuticals Factory Company SJSC with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 612 stocks
Beats the industry median on 11/13 measures
Overall it ranks above its industry peers.
Valuation
Quality Score77 · Top 25%
Fair Value upside−20% · Below median
Profitability
Return on equity (TTM)27% · Top 25%
Return on assets14% · Top 25%
Net margin (TTM)31% · Top 25%
Operating margin (TTM)33% · Top 25%
Growth and dividend
Revenue growth12% · Above median
Dividend yield (TTM)3.1% · Above median
Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Jamjoom Pharmaceuticals Factory Company SJSC Fair Value". https://www.fairvalue-calculator.com/stock/4015
Frequently asked questions
Is Jamjoom Pharmaceuticals Factory Company SJSC (4015) overvalued or undervalued?
As of Sep 13, 2026, our model estimates a fair value of 150.92 SAR versus a price of 136.10 SAR, about +11% upside (undervalued).
What is the fair value of 4015?
Our model-based fair value for Jamjoom Pharmaceuticals Factory Company SJSC is 150.92 SAR (as of Sep 13, 2026), built from audited fundamentals. The current price: 136.10 SAR.
What is the quality score of 4015?
Jamjoom Pharmaceuticals Factory Company SJSC has a Quality Score of 77/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Jamjoom Pharmaceuticals Factory Company SJSC (4015)?
Our model-based price target is the fair value of 150.92 SAR (as of Sep 13, 2026) from 24 valuation models. Cautious scenario 81.63 SAR, optimistic scenario 267.56 SAR. It is a calculation from audited fundamentals, not an analyst target.
What is the Jamjoom Pharmaceuticals Factory Company SJSC stock forecast for 2026?
Our models put fair value at 150.92 SAR, about +11% upside versus a price of 136.10 SAR (undervalued). Cautious scenario 81.63 SAR, optimistic scenario 267.56 SAR. The calculation is refreshed regularly with new filings.
What is the revenue of Jamjoom Pharmaceuticals Factory Company SJSC (4015)?
Jamjoom Pharmaceuticals Factory Company SJSC reported trailing-twelve-month revenue of about 1.6B SAR (latest available figure, as of Sep 13, 2026).
Does Jamjoom Pharmaceuticals Factory Company SJSC pay a dividend?
Jamjoom Pharmaceuticals Factory Company SJSC currently shows a dividend yield of about 3.09% relative to its recent price (as of Sep 13, 2026).
What growth is priced into Jamjoom Pharmaceuticals Factory Company SJSC (4015)?
For today's price to be fair in a discounted-cash-flow model, Jamjoom Pharmaceuticals Factory Company SJSC would have to grow free cash flow by +13.8 % per year for five years (discount rate 9.0 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +13.3 % per year. As of Sep 13, 2026.
What discount rate (WACC) does the fair value of 4015 use?
Our models discount Jamjoom Pharmaceuticals Factory Company SJSC at 9.0 %: a base by market capitalisation (mid), damped by beta 0.28, country premium for Saudi Arabia. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Jamjoom Pharmaceuticals Factory Company SJSC that is +13.8 % per year a year over ten years, using the same discount rate (9.0 %) and the same formula as our fair value.
How much growth has Jamjoom Pharmaceuticals Factory Company SJSC (4015) delivered so far?
Over the past 5 years revenue at Jamjoom Pharmaceuticals Factory Company SJSC grew +13.3 % a year. The price currently implies +13.8 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Jamjoom Pharmaceuticals Factory Company SJSC (4015) growing?
The median revenue growth in the sector is +4.3 % a year. That is the yardstick for the growth priced into Jamjoom Pharmaceuticals Factory Company SJSC (+13.8 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Jamjoom Pharmaceuticals Factory Company SJSC (4015)?
The free-cash-flow yield on the price is 3.47 %: that much free cash flow Jamjoom Pharmaceuticals Factory Company SJSC produces per unit of market value. When it exceeds the discount rate of our models (9.0 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Jamjoom Pharmaceuticals Factory Company SJSC (4015)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Jamjoom Pharmaceuticals Factory Company SJSC it is 150.92 SAR per share (as of Sep 13, 2026), against a price of 136.10 SAR. It is the blended result of 24 valuation models (cash flow, earnings, asset, dividend).
Is Jamjoom Pharmaceuticals Factory Company SJSC stock overvalued or undervalued in 2026?
As of Sep 13, 2026, 4015 trades below its calculated fair value: price 136.10 SAR, fair value 150.92 SAR, a gap of about +11% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 4015?
No. The price is what the market pays today (136.10 SAR); the fair value is what the company's own numbers justify (150.92 SAR). For Jamjoom Pharmaceuticals Factory Company SJSC the two are 14.82 SAR per share apart. That gap is exactly why we show both numbers side by side.
How much is Jamjoom Pharmaceuticals Factory Company SJSC worth?
The market values Jamjoom Pharmaceuticals Factory Company SJSC at about 9.6B SAR (market capitalisation, as of Sep 13, 2026). Per share that is 136.10 SAR; our models calculate a fair value of 150.92 SAR per share.
What do the bullish and bearish scenarios say about 4015?
Our models span a range for Jamjoom Pharmaceuticals Factory Company SJSC: cautious scenario 81.63 SAR, base 150.92 SAR, optimistic 267.56 SAR per share (as of Sep 13, 2026, price 136.10 SAR). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 4015?
Jamjoom Pharmaceuticals Factory Company SJSC trades at a price-to-earnings ratio of 20.0 (as of Sep 13, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of 150.92 SAR is built from several models across several years. Other multiples: P/B 1.5, P/S 1.6, EV/EBITDA 4.1.
How solid is the balance sheet of Jamjoom Pharmaceuticals Factory Company SJSC (4015)?
Balance-sheet figures for Jamjoom Pharmaceuticals Factory Company SJSC (as of Sep 13, 2026): return on equity 27.0%. They feed the Quality Score of 77/100, which measures business quality independently of the share price.
How far is 4015 from its 52-week high?
Jamjoom Pharmaceuticals Factory Company SJSC trades at 136.10 SAR, about 17% below its 52-week high of 164.50 SAR and 11% above the low of 123.13 SAR (as of Sep 13, 2026). Distance from the high says nothing about value: that is what the fair value of 150.92 SAR is for.
Which stocks are comparable to Jamjoom Pharmaceuticals Factory Company SJSC?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Jiangsu Hengrui Pharmaceuticals Co, Sun Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Jamjoom Pharmaceuticals Factory Company SJSC stock attractive at the current price?
The data as of Sep 13, 2026: price 136.10 SAR, calculated fair value 150.92 SAR (+11%), Quality Score 77/100, from 24 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 4015 calculated?
We run Jamjoom Pharmaceuticals Factory Company SJSC through 24 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 150.92 SAR, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 15.8 % above its aggregate fair value. Jamjoom Pharmaceuticals Factory Company SJSC currently trades 11 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What should I pay attention to with Jamjoom Pharmaceuticals Factory Company SJSC right now?
The model range is unusually wide (81.63 SAR to 267.56 SAR). The outcome hinges heavily on assumptions, so read the point estimate with caution. The price sits in the lower half of our model range, the side with the larger margin of safety. The data supports the verdict: every model runs on fully documented inputs.
Key figures of Jamjoom Pharmaceuticals Factory Company SJSC
How large is the market capitalisation of Jamjoom Pharmaceuticals Factory Company SJSC (4015)?
The market capitalisation of Jamjoom Pharmaceuticals Factory Company SJSC is 9.6B SAR (≈ $2.5B). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Jamjoom Pharmaceuticals Factory Company SJSC (4015)?
The price-to-sales ratio of Jamjoom Pharmaceuticals Factory Company SJSC is 6.20 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Jamjoom Pharmaceuticals Factory Company SJSC (4015)?
Earnings per share at Jamjoom Pharmaceuticals Factory Company SJSC are 6.79 SAR (price ÷ EPS = P/E 20.0). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Jamjoom Pharmaceuticals Factory Company SJSC (4015)?
The dividend yield of Jamjoom Pharmaceuticals Factory Company SJSC is 3.1% (payout 61.9%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Jamjoom Pharmaceuticals Factory Company SJSC (4015)?
The net margin of Jamjoom Pharmaceuticals Factory Company SJSC is 30.9% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Jamjoom Pharmaceuticals Factory Company SJSC (4015)?
The return on equity (ROE) of Jamjoom Pharmaceuticals Factory Company SJSC is 27.0% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Jamjoom Pharmaceuticals Factory Company SJSC (4015)?
On an EBIT basis the return on assets of Jamjoom Pharmaceuticals Factory Company SJSC is 18.7% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Jamjoom Pharmaceuticals Factory Company SJSC (4015)?
The operating margin of Jamjoom Pharmaceuticals Factory Company SJSC is 32.8% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Jamjoom Pharmaceuticals Factory Company SJSC (4015)?
Revenue at Jamjoom Pharmaceuticals Factory Company SJSC is growing +12.4% versus a year earlier (3y avg +17.9%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Jamjoom Pharmaceuticals Factory Company SJSC (4015)?
Earnings per share at Jamjoom Pharmaceuticals Factory Company SJSC are growing +4.2% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net cash does Jamjoom Pharmaceuticals Factory Company SJSC (4015) hold?
Jamjoom Pharmaceuticals Factory Company SJSC holds more cash than debt, 260M SAR net (fiscal year 2024). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch Jamjoom Pharmaceuticals Factory Company SJSC in the live analysis
One click puts Jamjoom Pharmaceuticals Factory Company SJSC on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
